<code id='154052C132'></code><style id='154052C132'></style>
    • <acronym id='154052C132'></acronym>
      <center id='154052C132'><center id='154052C132'><tfoot id='154052C132'></tfoot></center><abbr id='154052C132'><dir id='154052C132'><tfoot id='154052C132'></tfoot><noframes id='154052C132'>

    • <optgroup id='154052C132'><strike id='154052C132'><sup id='154052C132'></sup></strike><code id='154052C132'></code></optgroup>
        1. <b id='154052C132'><label id='154052C132'><select id='154052C132'><dt id='154052C132'><span id='154052C132'></span></dt></select></label></b><u id='154052C132'></u>
          <i id='154052C132'><strike id='154052C132'><tt id='154052C132'><pre id='154052C132'></pre></tt></strike></i>

          Home / entertainment / leisure time

          leisure time


          leisure time

          author:focus    Page View:6673
          Alexis Borisy
          Venture capitalist Alexis Borisy Vanessa Leroy for STAT

          EQRx is done, sold for its cash.

          The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

          advertisement

          The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In